Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines...
April 07 2021 - 3:03AM
Sanofi expands its social commitments, creates nonprofit unit to
provide poorest countries with access to essential medicines
Sanofi expands its social commitments, creates nonprofit
unit to provide poorest countries with access to essential
medicines
- Launch of a new and more impactful global corporate social
responsibility strategy
- Accelerating projects on access to medicines, support for
vulnerable communities, environmental conservation, and diversity
and inclusion
- Creation of Sanofi Global Health, global
nonprofit unit to provide 40 of the world’s poorest countries
access to 30 essential medicines
PARIS – April 7, 2021 – In an
open letter, Sanofi Chief Executive Officer Paul Hudson today
outlined several key projects that the company will implement to
increase the impact of its Corporate Social Responsibility (CSR)
strategy. Embedded in Sanofi's long-term strategy, the company’s
commitment is based on four essential pillars in which Sanofi is
uniquely positioned to make a difference: access to medicines,
support for vulnerable communities, preservation of the
environment, and inclusion and diversity of its employees.
“The pandemic has forced us to question nearly
every aspect of our lives: how we live and work, and how we connect
with our communities and the planet. Yet as challenging as 2020
was, it also brought us –Sanofi and the pharmaceutical industry–
closer to our purpose than at any other time in living memory,”
said Hudson. “This unique context led us to
elevate our ambition for our Corporate Social Responsibility
strategy and embed it even more into our mission to transform lives
and our vision for a better future.”
Sanofi Global Health, pillar of access
to essential medicinesA cornerstone of Sanofi’s CSR
strategy, Sanofi Global Health is a newly formed nonprofit unit
within the company. Leveraging the company’s diverse and large
portfolio of medicines and global footprint, Sanofi Global Health
is dedicated to increasing access to medicines considered essential
by the World Health Organization (WHO) for patients in 40
lower income countries. Thirty of Sanofi's
medicines will be provided across a wide range of therapeutic
areas, including cardiovascular disease, diabetes, tuberculosis,
malaria and cancer. Sanofi Global Health will also fund
the training of healthcare professionals or the set up and
development of sustainable care systems for those who suffer from
chronic diseases and require complex care.
Sanofi Global Health is the first global
initiative to provide access to such a broad portfolio of
medicines, in so many countries and across several therapeutic
areas, while funding local support programs.
Additionally, Sanofi is committed to helping
1,000 patients living with rare diseases who have no access
to treatments and will donate 100,000 vials of medicine for their
treatments each year. This continues Sanofi’s 30-year
commitment to patients suffering from rare diseases, such as Fabry,
Gaucher or Pompe diseases, for which access to treatment is often
limited.
Leveraging R&D efforts to address
crucial treatment gapsSanofi continues to support
vulnerable communities and commits to developing innovative
medicines for pediatric cancer, with the ultimate ambition
of eliminating cancer deaths in children. In low-
to middle-income countries, a child is four times more likely to
die of pediatric cancers than children living in high-income
countries.
Sanofi also continues its efforts to
fight polio and sleeping sickness, two of its
historical programs that address global health issues. In December
2020, Sanofi announced it had renewed its five-year partnership
with WHO to fight neglected tropical diseases that affect
approximately one billion people. In this context, Sanofi, the only
pharmaceutical company that keeps developing and supplying
treatments for African trypanosomiasis or sleeping sickness, has
committed itself alongside the WHO to eliminate this neglected
tropical disease in humans by 2030. For 40 years, Sanofi has
supplied billions of polio vaccine doses, including hundreds of
millions of donated doses to support the global polio eradication
effort.
Zero plastic packaging for vaccines and
ecodesign of productsFor several years, Sanofi has been
implementing a global environmental protection program, Planet
Mobilization. Today, the company is amplifying its actions to
further improve the environmental footprint of its products and
activities.
To reduce its greenhouse gas emissions by 55% by
2030 and contribute to better resource conservation, Sanofi plans
to remove all pre-formed plastic packaging (blister packs)
for its vaccines by 2027. The company is also committed to
ecodesigning all its new products by 2025. In
terms of energy management, all Sanofi sites will use 100%
renewable electricity and the company has set a target of
a carbon-neutral car fleet, both by 2030.
Pushing to build more diverse and
inclusive workforceAs a global company, Sanofi is
committed to ensuring that its leaders reflect the communities and
patients it serves. The company is committed to building an
organization where all employees have equal opportunities to reach
positions of responsibility within the company. Sanofi will
continue to build a workforce that is fully reflective of the
communities employees live in and the patients the company serves.
This element of the social impact strategy will be integrated into
the career development of Sanofi leaders worldwide, ensuring a
mindset that fosters diversity and inclusion throughout the
company.
“Throughout this pandemic, public authorities,
scientists, and industry have worked closely together to discover
and produce vaccines at a pace that has defied historical
precedent. We now have to apply this same sense of urgency to other
pressing threats, such as climate change, and issues that the
pandemic has sharply put into focus, including widening racial and
healthcare inequalities. Let’s always remember that crises do not
just neatly follow one after the other, they stack up. At Sanofi,
we know we can do more,” said Hudson.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations Contact Ashleigh Koss Tel: +1
(908) 981-8745Ashleigh.Koss@sanofi.com Sandrine
GuendoulTel.: +33 (0) 6 25 09 14 25Sandrine.Guendoul@sanofi.com
|
Investor Relations
Contacts Paris Eva Schaefer-Jansen Arnaud Delepine
Investor Relations Contacts North America Felix
LauscherFara BerkowitzSuzanne Greco IR main line:Tel.: +33
(0)1 53 77 45 45 investor.relations@sanofi.com
https://www.sanofi.com/en/investors/contact |
Forward-Looking StatementsThis press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
COVID-19 will have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a
whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2020. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements |
Sanofi (BIT:1SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024